<DOC>
	<DOC>NCT00748826</DOC>
	<brief_summary>The goal of this study is to implement instruments that would increase the treating physician's awareness of the necessary tuberculosis screening when starting a new patient on infliximab (Remicade) therapy who has not reacted sufficiently to disease-modifying preparations, including methotrexate.</brief_summary>
	<brief_title>Remicade Safety Line (Study P03236)(COMPLETED)</brief_title>
	<detailed_description>This study used a non-probability sampling method.</detailed_description>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients with active rheumatoid arthritis confirmed with adequate clinical response(ACR) criteria who did not react sufficiently to diseasemodifying preparations, including methotrexate, and who are receiving new treatment with infliximab. As per Summary of Product Characteristics (SmPC)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>